Clinical News - Ophthalmology Times

ADVERTISEMENT

Clinical News

Glaucoma progression software receives clearance from FDA

Jul 1, 2009

Software (MatchedFlicker, EyeIC) that monitors the advent and progression of glaucoma through retinal photography has received FDA 510(k) clearance.

FDA approves implant for macular edema associated with RVO

Jul 1, 2009

The FDA has approved dexamethasone intravitreal implant 0.7 mg (Ozurdex, Allergan) for the treatment of macular edema following branch retinal vein occlusion or central retinal vein occlusion.

IOL injector system given 510(k) clearance

Jul 1, 2009

The FDA has granted 510(k) clearance for an injector system (Epiphany, STAAR Surgical Co.) designed for use with a three-piece new-technology IOL ([NTIOL]; Affinity Collamer, STAAR Surgical) and a silicone NTIOL (Elastimide, STAAR Surgical), according to the devices' manufacturer.

Besifloxacin approved for use against ocular infections

Topical ophthalmic fluoroquinolone treats broad range of bacterial ocular pathogens
Jul 1, 2009

Besifloxacin ophthalmic suspension 0.6% (Besivance, Bausch & Lomb) is a new topical ophthalmic antibacterial indicated for the treatment of bacterial conjunctivitis and administered via sterile ophthalmic drops.

Committee recommends approval of bepotastine for ocular itching

Jul 1, 2009

The Dermatologic and Ophthalmic Drugs Advisory Committee appointed by the FDA has recommended the approval of bepotastine besilate ophthalmic solution 1.5% (Bepreve, ISTA Pharmaceuticals Inc.) as an eye-drop treatment for ocular itching associated with allergic conjunctivitis, according to the company.

Dry eye diagnosis could be aided by tear osmolarity device

Jul 1, 2009

The FDA has given 501(k) clearance to the TearLab Osmolarity System, a new device that measures the osmolarity of tears to aid in the diagnosis of dry eye disease.

Omega-3 fatty acids may prevent progression of AMD, according to study

Jun 22, 2009

Omega-3 fatty acids found in fish such as tuna and salmon may protect against progression of age-related macular degeneration (AMD).

Dexamethasone receives FDA approval for the treatment of RVO

Jun 18, 2009

Dexamethasone intravitreal implant 0.7 mg (Ozurdex, Allergan), indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO), has been approved by the FDA. Retinal vein occlusion including BRVO and CRVO is the second most common retinal vascular disease after diabetic retinopathy.

CCR3 linked to neovascular AMD, according to researchers

Jun 17, 2009

Researchers identified a biological marker, CCR3, which is linked to the development and progression of neovascular age-related macular degeneration (AMD).

ADVERTISEMENT

ADVERTISEMENT

Ophthalmology Times issue
Stay connected to Ophthalmology Times
Receive new issue alerts, technology bulletins, and conference updates!

ADVERTISEMENT

What Do You Think?
Have fireworks caused an eye injury in any of your patients?
Yes
No
View Results
Yes
89%
No
11%
View Results
Click here